NCT00774072

Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization

Nasal Inhalation of Tobramycin by the Pari Sinus Nebulizer in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization in the Upper Airways

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: University of Jena · Academic / Other
• Sex: All
• Age: 8 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether the nasal inhalation of Gernebcin® is effective to decrease the Pseudomonas aeruginosa bacterial count in the nasal lavage fluid.

Conditions

• Cystic Fibrosis
• Pseudomonas Aeruginosa

Interventions

Type	Name	Description
DRUG	Tobramycin (Gernebcin®)	1 ml / day in each nostril

Timeline

• Start date: 2008-10-01
• Primary completion: 2010-11-01
• Completion: 2010-11-01
• First posted: 2008-10-17
• Last updated: 2014-12-04

Locations

2 sites across 1 country: Germany